Article
Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
Molecular cancer research : MCR - 1 Jul 2018
Stronach Euan A, Paul James, Timms Kirsten M, Hughes Elisha, Brown Krystal, Neff Christopher, Perry Michael, Gutin Alexander, El-Bahrawy Mona, Steel Jennifer H, Liu Xinxue, Lewsley Liz-Anne, Siddiqui Nadeem, Gabra Hani, Lanchbury Jerry S, Brown Robert
Abstract excerpt
The current study evaluated three biomarkers [homologous recombination deficiency (HRD), tumor BRCA1/2 (tBRCA) mutations, and CCNE1 copy-number variation (CNV)] in ovarian tumors from patients enrolled on the SCOTROC4 clinical trial for associations with outcome following carboplatin monotherapy. Ovarian tumors (n = 250), with high-grade serous (HGSOC) subgroup analysis (n = 179) were classified as HRD positive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.